Tumor targeting: activation of prodrugs by enzyme-monoclonal antibody conjugates.

No abstract is available for this paper.

• Publication year

  1994

• Venue

  Trends in Biotechnology

• Publication date

  1994-06-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/0167-7799(94)90122-8PMID 7765070
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Genetic construction, expression, and characterization of a single chain anti-carcinoma antibody fused to beta-lactamase.

  1993cited by this paper
• Activation by peptidases and cytotoxicity of 2-(L-alpha-aminoacyl) prodrugs of methotrexate.

  1993cited by this paper
• Synthesis of acylhydrazido-substituted cephems. Design of cephalosporin-vinca alkaloid prodrugs: substrates for an antibody targeted enzyme

  1992cited by this paper
• Preparation and characterization of a beta-lactamase-Fab' conjugate for the site-specific activation of oncolytic agents.

  1992cited by this paper
• Activation of methotrexate-alpha-alanine by carboxypeptidase A-monoclonal antibody conjugate.

  1992cited by this paper
• Specific activation of glucuronide prodrugs by antibody-targeted enzyme conjugates for cancer therapy.

  1992cited by this paper
• Activation of Methotrexate Prodrugs by Enzyme/Monoclonal Antibody Conjugates

  1991cited by this paper
• Construction and chemotherapeutic potential of carboxypeptidase-A/monoclonal antibody conjugate.

  1991cited by this paper
• Generation of 5-fluorouracil from 5-fluorocytosine by monoclonal antibody-cytosine deaminase conjugates.

  1991cited by this paper
• Activation of prodrugs by antibody‐enzyme conjugates: a new approach to cancer therapy

  1990cited by this paper
• Specific activation of the prodrug mitomycin phosphate by a bispecific anti-CD30/anti-alkaline phosphatase monoclonal antibody.

  1990cited by this paper
• Mitotoxins: growth factor-targeted cytotoxic molecules.

  1990cited by this paper
• Biosynthesis and glycosylation of the carcinoma-associated antigen recognized by monoclonal antibody KS1/4.

  1990cited by this paper
• Carboxypeptidase-mediated release of methotrexate from methotrexate alpha-peptides.

  1989cited by this paper
• Enhancement of the in vitro and in vivo antitumor activities of phosphorylated mitomycin C and etoposide derivatives by monoclonal antibody-alkaline phosphatase conjugates.

  1989cited by this paper
• The First Bagshawe lecture. Towards generating cytotoxic agents at cancer sites.

  1989cited by this paper
• A cytotoxic agent can be generated selectively at cancer sites.

  1988cited by this paper
• Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report.

  1988cited by this paper
• Anti-tumor effects of antibody-alkaline phosphatase conjugates in combination with etoposide phosphate.

  1988cited by this paper
• Chemistry and biology of pteridines: a Ciba Foundation Symposium, edited by G.E.W. Wolstenholme, J. and A. Churchill, Ltd., London. 1954. 425 pages, 42s

  1956cited by this paper

• Recent Progress in Biopharmaceutical Drugs Research and Development

  2017cites this paper
• Anticancer substances of mushroom origin.

  2014cites this paper
• Chapter 289 – Carboxypeptidase A

  2013cites this paper
• Encapsulation of paclitaxel into lauric acid-O-carboxymethyl chitosan-transferrin micelles for hydrophobic drug delivery and site-specific targeted delivery.

  2013cites this paper
• Rekombinante Antikörper-Enzym-Fusionskonstrukte zur zielgerichteten Therapie kolorektaler Karzinome

  2010cites this paper
• Biopharmaceuticals: An Industrial Perspective

  2009cites this paper
• Novel Gene Therapeutic Approaches to Brain Cancer

  2006cites this paper
• Methotrexate-a-Phenylalanine: Optimization of Methotrexate Prodrug for Activation by Carboxypeptidase A-Monoclonal Antibody Conjugate1

  2006cites this paper
• 240 – Carboxypeptidase A

  2004cites this paper
• A new paclitaxel prodrug for use in ADEPT strategy.

  2003cites this paper
• Internalization of Antibodies

  2002cites this paper
• Selective chemotherapeutic strategies using catalytic antibodies: a common pro-moiety for antibody-directed abzyme prodrug therapy.

  2002cites this paper
• Paclitaxel immunoconjugate for the specific treatment of ovarian cancer in vitro.

  2001cites this paper
• Antibody engineering at the millennium.

  2000cites this paper
• Prodrugs of natural anthracycleves suited for antibody directed enzyme prodrug therapy (ADEPT) and prodrug monotherapy (PMT)

  2000cites this paper
• The EGF receptor as central transducer of heterologous signalling systems.

  1999cites this paper
• High cytoplasmic expression in E. coli, purification, and in vitro refolding of a single chain Fv antibody fragment against the hepatitis B surface antigen.

  1999cites this paper
• Biopharmaceuticals, an overview

  1999cites this paper
• Prodrugs of anthracyclines for use in antibody-directed enzyme prodrug therapy.

  1998cites this paper
• Overexpression of Human Procarboxypeptidase A2 in Pichia pastoris and Detailed Characterization of Its Activation Pathway*

  1998cites this paper
• Lipoamino acid conjugates of methotrexate with antitumor activity.

  1998cites this paper
• Novel therapeutic strategies to selectively kill cancer cells.

  1998cites this paper
• Synthesis of self-immolative glucuronide-based prodrugs of a phenol mustard.

  1998cites this paper
• The three‐dimensional structure of human procarboxypeptidase A2. Deciphering the basis of the inhibition, activation and intrinsic activity of the zymogen

  1997cites this paper
• Toward Antibody-directed Enzyme Prodrug Therapy with the T268G Mutant of Human Carboxypeptidase A1 and Novel in VivoStable Prodrugs of Methotrexate*

  1997cites this paper
• Development of methotrexate alpha-peptides as prodrugs for activation by enzyme-monoclonal antibody conjugates.

  1997cites this paper
• Designed protein pores as components for biosensors.

  1997cites this paper
• Antibody-directed enzyme prodrug therapy (ADEPT): a review.

  1997cites this paper
• Prodrugs of anticancer agents

  1996cites this paper
• Production of recombinant antibody fragments in microorgansms.

  1996cites this paper
• Design of a drug delivery system for targeting based on pharmacokinetic consideration

  1996cites this paper
• Trends in Drug Targeting for Cancer Treatment

  1996cites this paper
• Pharmacokinetics of Monoclonal Antibodies

  1996cites this paper
• Section Review: Biologicals & Immunologicals: Development of prodrugs for ADEPT (antibody-directed enzyme prodrug therapy)

  1996cites this paper
• Tumor protease-activated, pore-forming toxins from a combinatorial library

  1996cites this paper
• Synthesis and evaluation of 4-substituted analogues of 5-[N,N-bis (2-chloroethyl)amino]-2-nitrobenzamide as bioreductively activated prodrugs using an Escherichia coli nitroreductase.

  1996cites this paper
• A novel nitro-substituted seco-CI: Application as a reductively activated adept prodrug

  1996cites this paper
• Prodrugs of anthracycline antibiotics suited for tumor-specific activation.

  1995cites this paper
• Phloem mobility of xenobiotics VI. A phloem‐mobile pro‐nematicide based on oxamyl exhibiting root‐specific activation in transgenic tobacco

  1995cites this paper
• Methotrexate-alpha-phenylalanine: optimization of methotrexate prodrug for activation by carboxypeptidase A-monoclonal antibody conjugate.

  1995cites this paper
• A NOVEL ENEDIYNE PRODRUG FOR ANTIBODY-DIRECTED ENZYME PRODRUG THERAPY (ADEPT) USING E. COLI B NITROREDUCTASE

  1995cites this paper
• Synthesis and evaluation of novel daunomycin-phosphate -sulfate -beta-glucuronide and -beta-glucoside prodrugs for application in ADEPT.

  1995cites this paper
• BETA-GLUCURONYL CARBAMATE BASED PRO-MOIETIES DESIGNED FOR PRODRUGS IN ADEPT

  1995cites this paper